Abstract
Purpose :
To evaluate safety and efficacy of topically administered 0.024% latanoprostene bunod ophthalmic solution (Vyzulta™; Bausch & Lomb) in glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).
Methods :
Twenty glaucomatous Beagle dogs with ADAMTS10-OAG, 10 females and 10 males, between the ages of 2.4-4.9 years (median: 2.7 years) were used. In each dog, left or right eye was randomly selected for latanoprostene bunod treatment. Contralateral eyes were treated with generic 0.005% latanoprost ophthalmic solution with well established canine efficacy and safety. Part 1 (n = 15 dogs) consisted of a 4-week study with diurnal intraocular pressure (IOP) and pupil diameter being the main efficacy outcome measures: Following a baseline period (Week 1), dogs were treated once (q24h, Week 2) and twice daily (q12h, Week 3); Week 4 served as washout period. In Part 2 (n=11 dogs), IOPs were monitored for 8 hours following a 1-time drug administration. Safety was assessed by routine ophthalmic examination, gonioscopy and pachymetry. Differences in least square means of quantitative outcome measures were compared between latanoprostene bunod and latanoprost treated eyes by linear Gaussian model.
Results :
Mean baseline IOP was 30.0 ± 3.1 mmHg (mean ± SEM). While there were significant decreases in IOPs and pupil diameters for both treatments (p < 0.0001), there were no differences in IOP treatment effects between latanoprostene bunod and latanoprost (q24h: 15.1 ± 1.3 mmHg vs. 15.9 ± 1.3 mmHg; q12hr: 13.1 ± 1.1 mmHg vs. 14.1 ± 1.1 mmHg). Furthermore, there was no difference in short-term IOP effect over 8 hours between the 2 drugs. Both latanoprostene bunod and latanoprost administration resulted in mild to moderate conjunctival hyperemia.
Conclusions :
Once or twice daily administration of latanoprostene bunod and latanoprost were equally effective in lowering IOP in glaucomatous dogs with no detectable treatment effect resulting from latanoprostene bunod’s nitric oxide (NO) donating moiety.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.